Nilofar Rahman, MD RISK OF RECURRENCE OF CLOSTRIDIUM DIFFICILE INFECTION WITH PPI USE
CLOSTRIDIUM DIFFICILE ORGANISM Identified in 1978 “J strain” B1/NAP1/027 strain
INCIDENT RATES IF C. DIFF. INFECTION
EPIDEMIOLOGY OF C. DIFF INFECTION
RISK FACTORS FOR RECURRENCE OF CDI Advanced age Non- CDI targeted antibiotic exposure Longer hospital stay Inadequate antitoxin-antibody response Concomitant use of PPIs
PATHOGENESIS OF C. DIFF INFECTION Antibiotic therapy Disruption of gut flora Toxin production C. Diff exposure
PROBABILITY OF RECURRENCE OF C. DIFF WITH VANC.(TOP) AND METRONIDAZOLE(BELOW)
STUDY DONE BY LINSKY ET AL. STUDY DESIGN 1549 Incident c. diff toxin 1408 treated with oral metronidazole or vancomycin 1166 treated within 3 d before or after index CDI 527 PPI exposure639 no PPI exposure
Study population
PRIMARY EXPOSURE AND OUTCOMES Exposure measure : PPI within 14 days Outcome measure: C. diff toxin in after incident CDI Covariates: Age, sex Comorbid conditions CDI- targeted antibiotic Non-CDI targeted antibiotic
RESULTS
ModelHazard ratio(95% CI)P value Unadjusted1.42( )0.006 Adjusted1.42( )0.008 Non-CDI antibiotic exposure 1.71( )0.01 No antibiotic exposure 1.30( )0.12 RESULTS CONTD..
Study done by Kim et al.
EXPOSURE VARIABLE AND STUDY DESIGN Exposure variable: PPI use 3D prior to CDI Study design Recurrent group Non-recurrent group
RESULTS Age > 65 (60%, P=0.02) Fed via NGT (48.1%, P=0.04) Low albumin ( 2.3+/- 0.5g/dl vs /- 0.4g/dl) PPI use (63% vs 39.8%, P=0.01) UNIVARIATE ANALYSIS
RISK FACTORSADJUSTED ODDS RATIO CI (95%)P VALUE Age> Concurrent PPI use Serum albumin<2.5g/dl NGT MULTIVARIATE ANALYSIS
Since use of PPIs is a modifiable risk factor for recurrence it is appropriate to review, constantly, the use of PPIs in patients with CDI.
THANK YOU
REFERENCES